Drug found to slow Alzheimer’s by up to 60 percent in trial

A new drug has been hailed as a “breakthrough” after it was found to slow the progression of Alzheimer’s disease by 60 percent if started when patients are in the earliest stages of the brain-wasting disease, according to a new study.
The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60 percent if the drug is started when patients are only mildly impaired, according to new trial data presented by Eli Lilly on Monday at the Alzheimer’s Association International Conference in Amsterdam.
The full analysis presented by the American pharmaceutical company showed results were less robust for older, later-stage patients as well as those with higher levels of a protein called tau, which has been linked to Alzheimer’s disease progression.

Al Jazeera’s Step Vaessen reports from Amsterdam.

Subscribe to our channel: http://bit.ly/AJSubscribe
Follow us on Twitter: https://twitter.com/AJEnglish
Find us on Facebook: https://www.facebook.com/aljazeera
Check our website: http://www.aljazeera.com/
Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/

#Alzheimers #Donanemab #EliLilly #AlJazeeraEnglish